Instructions Avenue film-coated tablets 500 mg blister No. 50
Composition
active ingredient: 1 tablet contains 500 mg of micronized purified flavonoid fraction (calculated as 100% anhydrous substance), which contains 450 mg of diosmin (90%) and 50 mg of flavonoids in the form of hesperidin (10%);
excipients: polyvinyl alcohol, microcrystalline cellulose, sodium starch glycolate (type A), talc, magnesium stearate, Opadry II 85F34486 Pink (polyvinyl alcohol, titanium dioxide (E 171), polyethylene glycol (macrogol), talc, red iron oxide (E 172), yellow iron oxide (E 172)).
Dosage form
Film-coated tablets.
Main physicochemical properties: oval-shaped tablets with a biconvex surface, with a score on one side, film-coated, light pink in color with a faint brown tint.
Pharmacotherapeutic group
Capillary stabilizing agents. Bioflavonoids. Diosmin, combinations. ATX code C05C A53.
Pharmacological properties
Pharmacodynamics
Avenue® has a venotonic and angioprotective effect, increases venous tone, reduces venous distensibility and venostasis, improves microcirculation, reduces capillary permeability and increases their resistance, improves lymphatic drainage, increasing lymphatic outflow.
The drug also reduces the interaction of leukocytes and endothelium, leukocyte adhesion in postcapillary venules. This reduces the damaging effect of inflammatory mediators on the walls of veins and the leaflets of vein valves.
Pharmacokinetics
The half-life is 11 hours.
The active substance is excreted mainly through the intestines. An average of 14% of the administered dose is excreted in the urine.
Indication
Symptomatic treatment of venolymphatic insufficiency (heaviness in the legs, pain, swelling).
Symptomatic treatment of hemorrhoids.
Contraindication
Hypersensitivity to the active substance or to any of the excipients.
Interaction with other medicinal products and other types of interactions
Interaction studies have not been conducted. However, there is extensive post-marketing experience with diosmin, and no interactions with other drugs have been reported to date.
Application features
The use of this medicinal product for acute hemorrhoids does not replace specific treatment and does not interfere with the treatment of other proctological diseases. If the symptoms do not disappear quickly during a short course of treatment, a proctological examination should be performed and the therapy reviewed.
In cases of venous circulation disorders, more effective treatment is provided by combining therapy with adherence to the following lifestyle recommendations:
- avoid prolonged exposure to the sun, prolonged standing, and excess body weight;
- walk and in some cases wear special stockings to improve blood circulation.
Use during pregnancy or breastfeeding
Pregnant women should use the drug with caution. Consult a doctor before use.
Studies have not revealed any teratogenic effects of the drug, and no side effects have been reported.
Due to the lack of data on the penetration of the drug into breast milk, the use of the drug during breastfeeding should be avoided.
Ability to influence reaction speed when driving vehicles or other mechanisms
The drug does not affect the ability to drive vehicles and work with various mechanisms. In case of signs of side effects of the drug (see the section "Adverse reactions"), caution should be exercised.
Method of administration and doses
For oral use. For adults.
Treatment of venolymphatic insufficiency (symptoms: swelling, pain, heaviness in the legs, night cramps, trophic ulcers, lymphedema).
The recommended dose is 2 tablets per day: 1 tablet in the afternoon and 1 tablet in the evening, with meals. After a week of use, you can take 2 tablets per day once during meals.
Treatment of chronic hemorrhoids.
2 tablets per day (in two divided doses) with meals. After a week of use, you can take 2 tablets per day once with meals.
Treatment of acute hemorrhoids.
6 tablets per day for 4 days, then 4 tablets per day for the next 3 days. Take with meals. Divide the daily amount of tablets into 2-3 doses.
Treatment course. The duration of treatment depends on the indication for use and the course of the disease. The average duration of treatment is 2-3 months.
Children
There are no data on the use of Avenue® in children.
Overdose
No cases of overdose have been reported.
Adverse reactions
From the nervous system: dizziness, headache, malaise.
Gastrointestinal: diarrhea, dyspepsia, nausea, vomiting, colitis.
Skin and subcutaneous tissue disorders: rash, itching, urticaria, isolated swelling of the face, lips, eyelids, angioedema.
Expiration date
2 years.
Do not use the drug after the expiration date indicated on the package.
Storage conditions
Store in original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Packaging
10 tablets in a blister. 3 or 5 blisters in a pack.
Vacation category
Without a prescription.
Producer
PJSC "Farmak".
Location of the manufacturer and its business address
Ukraine, 04080, Kyiv, Frunze St., 74.
